Rehan Khan Explores Clopidogrel
Rehan Khan, Hospital Pharmacist and Manager Auctus Hospital, shared on LinkedIn:
”Day 2/365 – Medicine of the Day: CLOPIDOGREL
One-Sentence Definition
Clopidogrel is an antiplatelet drug used to prevent blood clot formation in patients with cardiovascular and cerebrovascular diseases.
Pharmacological Overview
Drug class: Antiplatelet agent (P2Y₁₂ receptor inhibitor)
Drug type: Prodrug
Primary role: Prevention of arterial thrombosis
Therapeutic Uses
- Acute Coronary Syndrome (ACS)
- Post–myocardial infarction (MI)
- Stroke and TIA prevention
- After coronary stent placement
- Alternative in aspirin intolerance
Mechanism of Action (MOA)
- Inhibits ADP (P2Y₁₂) receptors on platelets
- Prevents activation of GPIIb/IIIa complex
- Lowers Platelet aggregation
- Effect lasts for platelet lifespan (7–10 days)
Common Dose
- Maintenance dose: 75 mg once daily
- Loading dose (ACS/PCI): 300–600 mg stat
Key Adverse Effects
Bleeding (most common)
Gastrointestinal upset
Rare: Thrombotic thrombocytopenic purpura (TTP)
Clinical Pearl
Clopidogrel is a prodrug—its efficacy depends on liver enzyme activation (CYP2C19).
HISTORY OF CLOPIDOGREL
1980s: Development of thienopyridine antiplatelets
1997: Clopidogrel approved for clinical use
CAPRIE trial: Showed superiority over aspirin in reducing ischemic events
Modern era: Backbone of dual antiplatelet therapy (DAPT) with aspirin
Why Clopidogrel Matters
- Essential in cardiology and interventional practice
- Life-saving in stent patients
- WHO essential cardiovascular medicine
Widely used globally in ACS protocols”

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 13:50Louise Maes: CONVINCE Trial Imaging Studies Reveal New Insights Into Carotid Plaque and Vascular Risk
-
Nov 20, 2026, 13:50Lara Kurdi: A Presentation of Triple-Positive Antiphospholipid Syndrome
-
Nov 20, 2026, 13:46Rahul Bohra: Beyond Platelet Counts – The Lived Experience of ITP
-
Nov 20, 2026, 13:34Yohei Hisada: How Well Do Mouse Leukemia Models Reflect Human Disease?
-
Nov 20, 2026, 13:20Ilenia Calcaterra: The Inferior Thyroid Arteries as a Window Into Cardiovascular Risk
-
Nov 20, 2026, 13:03Does Being Fit Protect Against VTE? – RPTH Journal
-
Nov 20, 2026, 12:29Thirunavukkarasu Angappan: Antithrombin in ECMO – Two Datasets, Two Opposite Answers
-
Nov 20, 2026, 11:38Muhammad Kashif: Therapeutic Plasma Exchange – Key Concepts at a Glance
-
Nov 20, 2026, 11:33Tyler McConville: Why Hemostatic Function Matters More Than Cell Counts in Trauma and Transfusion